The Healthy @Reader's Digest on MSN4d
“How I Knew I Had Ovarian Cancer”: A Patient’s Story Reveals an Unexpected Benefit of Daily ExerciseA woman's story of literal strength shows how ovarian cancer can be missed—and the lighthearted recovery milestone every care ...
A new drug tested in a phase 3 trial showed significant improvement in patients with treatment-resistant ovarian cancer.
The SB221 trial was structured to evaluate the combination’s tolerability, pharmacodynamics, safety and pharmacokinetics.
A phase 3 trial of nemvaleukin alfa in with Keytruda for patients with platinum-resistant ovarian cancer will not continue on ...
News-Medical.Net on MSN1d
Uncommon ovarian tumors detected in a single patientA new case report was published in Oncoscience's Volume 12 on March 31, 2025, titled "Cystadenofibroma and contralateral collision lesions: A unique ovarian case report." ...
A new case report was published in Oncoscience’s Volume 12 on March 31, 2025, titled “Cystadenofibroma and contralateral ...
The first patient was dosed in a phase 3 trial of IBI354 for platinum-resistant ovarian cancer with HER2 expression.
New phase 3 data provide reassurance on safety, tolerability, and overall benefit-risk of mirvetuximab soravtansine (Elahere) ...
Corcept Therapeutics (CORT.O), opens new tab said on Monday its experimental drug in combination with chemotherapy helped delay progression of a type of ovarian cancer in a late-stage trial.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback